EFPIA: Invest early in health to save later

US MFN pricing could make Sweden a global price anchor

Denmark weighs allergy medicine reimbursement, with shifts for Grazax

NICE recommends zanidatamab for HER2-positive advanced biliary tract cancer

NICE backs Jaypirca in draft guidance for relapsed CLL

NICE recommends Blenrep for relapsed multiple myeloma

NICE seeks feedback on new EQ-5D-5L value set

The Danish Association of the Pharmaceutical Industry (LIF) warns: MFN could intensify pressure on Denmark’s drug reimbursement system.

TLV publishes health economic assessment of Blenrep

Socialstyrelsen establishes SweCan to coordinate cancer innovation